Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
10:20pm, Thursday, 12'th Feb 2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat
OKYO Pharma Announces Public Offering of Ordinary Shares
04:01pm, Thursday, 12'th Feb 2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
11:17am, Wednesday, 11'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases, announced that it has transitioned its At-The-
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
10:09am, Wednesday, 11'th Feb 2026
LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
Shopify shares slide despite Q4 revenue and EPS beat
07:22am, Wednesday, 11'th Feb 2026
Shopify Inc (TSX:SH., NYSE:SHOP) shares were down nearly 13% on Wednesday, even as the e-commerce platform reported fourth-quarter revenue and earnings per...
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
06:03am, Wednesday, 11'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases,...
Dow hits new high but early gains cut, Mattel and Lyft plunge
05:39am, Wednesday, 11'th Feb 2026
10:35am: Stronger-than-expected jobs report The US labor market showed signs of strength in January, with job creation doubling expectations, even as final...
US job strength signals Fed may hold off on additional rate cuts
05:34am, Wednesday, 11'th Feb 2026
The US economy added 130,000 jobs in January, well above economists’ expectations, while the unemployment rate fell to 4.3%, signaling a labor market that...
OKYO Pharma appoints Flavio Mantelli as chief medical officer
09:39am, Tuesday, 10'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, has appointed Flavio Mantelli as its Ch
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
08:00am, Tuesday, 10'th Feb 2026
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantel
Datadog shares surge after Q4 earnings beat
07:18am, Tuesday, 10'th Feb 2026
Datadog Inc (NASDAQ:DDOG) shares jumped 16% on Tuesday after the cloud monitoring and security company reported fourth-quarter results that beat Wall Street...
OKYO Pharma appoints Flavio Mantelli as chief medical officer
04:36am, Tuesday, 10'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye...
AMD seen delivering modest Q4 beat on PC and server strength
08:27am, Monday, 02'nd Feb 2026
Advanced Micro Devices (NASDAQ:AMD) will report its fourth quarter earnings on Tuesday, with Wedbush analysts expecting a solid performance from the...
OKYO Pharma's neuropathic corneal pain study greenlit by FDA - ICYMI
11:03am, Saturday, 31'st Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week confirmed it is set to launch a Phase 2b/3 clinical trial for neuropathic corneal pain, following a productive Type C meeting with the US Food and Drug
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting
12:16pm, Friday, 30'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that an abstract on its lead
